Nataliya Tovbis Shifrin

Nataliya Tovbis Shifrin is a Senior Scientist II at REVOLUTION Medicines, where work includes independent research on factors affecting the anti-tumor efficacy of anti-PD1 treatment, notably demonstrating that IL-27 cytokine impairs tumor regression. Prior experience includes roles as a Senior Scientist at ARMO BioSciences, and postdoctoral fellow at Merck, focusing on immunological studies. Academic qualifications include a PhD in Immunology and a Bachelor's degree in Cellular and Molecular Biology, both from the University of California, Berkeley. Research experience also includes conducting studies on the response and tolerance of Natural Killer cells at UC Berkeley, and investigating the ubiquitin-modifying enzyme A20 at UCSF.